Prothrombin and risk of venous thromboembolism, ischemic heart disease and ischemic cerebrovascular disease in the general population

Atherosclerosis. 2010 Feb;208(2):480-3. doi: 10.1016/j.atherosclerosis.2009.05.006. Epub 2009 May 21.


Objective: We tested the hypotheses that Prothrombin G20210A heterozygosity associate with increased risk of venous thromboembolism (VTE), ischemic heart disease (IHD), and ischemic cerebrovascular disease (ICVD) in the general population and re-tested risk of IHD and ICVD in two case-control studies.

Methods: 9231 individuals from the Danish general population were followed for VTE (VTE=DVT+PE), deep venous thrombosis (DVT), pulmonary embolism (PE), IHD, myocardial infarction (MI), ICVD, and ischemic stroke (IS) for a median of 24 years. Case-control studies included 2461 IHD cases and 867 ICVD cases.

Results: In the general population, Prothrombin G20210A heterozygotes had1.3 (95% CI:0.6-2.9) fold risk for VTE, 0.6 (0.2-2.0) for DVT, 1.7(0.6-4.8) for PE, 1.5(1.1-2.1) for IHD, 1.7(1.1-2.7) for MI, 1.1(0.6-1.9) for ICVD, and 1.1(0.5-2.1) for IS compared to non-carriers. Double heterozygotes for Prothrombin G20210A and Factor V Leiden versus double non-carriers had a multifactorially adjusted hazard ratio for IHD of 6.0(2.0-19). In case-control studies, multifactorially adjusted odds ratios for Prothrombin G20210A heterozygotes versus non-carriers were 2.0(1.1-3.4) for IHD, 2.0(1.0-3.8) for MI, 1.4(0.7-3.1) for ICVD, and 2.1(0.8-5.4) for IS.

Conclusion: Prothrombin G20210A heterozygosity alone and in combination with Factor V Leiden R506Q heterozygosity predicts 1.5 and 6.0 fold risk of IHD compared to non-carriers.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Case-Control Studies
  • Cerebrovascular Disorders / therapy*
  • Denmark
  • Heterozygote
  • Humans
  • Ischemia / pathology*
  • Myocardial Infarction / blood
  • Myocardial Infarction / therapy
  • Myocardial Ischemia / therapy*
  • Odds Ratio
  • Proportional Hazards Models
  • Prothrombin / genetics*
  • Prothrombin / metabolism*
  • Pulmonary Embolism / blood
  • Pulmonary Embolism / therapy
  • Risk
  • Stroke / blood
  • Stroke / therapy
  • Venous Thromboembolism / blood*
  • Venous Thromboembolism / therapy


  • Prothrombin